Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Lexaria Bioscience Corp
LEXX
Alternate Symbol(s):
LEXXW
Healthcare
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Company’s patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the...
bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue. The Company has also developed DehydraTECH formulations for other applications demonstrating bio-absorption when administered intraorally and topically. It operates through two segments: Intellectual Property and Products. It also operates a licensed in-house research laboratory and holds an intellectual property portfolio with 35 patents granted and many patents pending worldwide. Its subsidiaries include Lexaria CanPharm ULC, and Lexaria CanPharm Holdings Corp.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:LEXX)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(208)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Aug 29, 2024 2:01pm
Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse
Breaking News: $LEXX Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral CapsulesAbsorption improvements appear to continue with
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Aug 29, 2024 9:30am
New Press Release - Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules
Absorption improvements appear to continue with DehydraTECH-processed Rybelsus® vs. Rybelsus® tablets even under "fed" conditionsDehydraTECH-treated Rybelsus® does absorb through a mouth-melt product formatKELOWNA, BC / ACCESSWIRE / August 29, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ...
read article.
NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets
posted Nov 14, 2024 9:00am by
NurExone Biologic Inc.
-
|
“We are honored by the EMA’s recognition of ExoPTEN through the Orphan Medicinal Product Designation, which significantly advances our ability to enter the European market and offers hope to those impacted by acute spinal cord injuries,” said Dr. Lior Shaltiel, Chief Executive Officer of NurExone. “This designation, together with the ...read more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Aug 29, 2024 9:25am
New Press Release - Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus Oral Capsules
(TheNewswire)Absorption improvements appear to continue with DehydraTECH-processed Rybelsus® vs. Rybelsus® tablets even under “fed” conditionsDehydraTECH-treated Rybelsus® does absorb through a mouth-melt product formatKelowna, British Columbia – August 29, 2024 – TheNewswire – Lexaria Bioscience...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Aug 27, 2024 9:20am
New Press Release - First Results from Lexaria's Second GLP-1 Human Pilot Study
(TheNewswire)Trend toward higher overall absorption under fed conditions evidenced with DehydraTECH®-processed Rybelsus® Kelowna, British Columbia – TheNewswire - August 27, 2024 – Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Aug 22, 2024 9:20am
New Press Release - Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
(TheNewswire)DehydraTECH-liraglutide is outperforming DehydraTECH-semaglutideSelect DehydraTECH-CBD formulations appear to continue to outperform DehydraTECH-semaglutideKelowna, British Columbia – August 22, 2024 – TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the “Company” or...
read article.
(208)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Aug 21, 2024 9:00pm
InvestorNewsBreaks - Lexaria Bioscience Corp. (NASDAQ: LEXX)
Breaking News: $LEXX InvestorNewsBreaks - Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Interim Animal Study Results Supporting Potential Utility of DehydraTECH-CBD in Diabetes
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Aug 21, 2024 9:01am
New Press Release - Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
(TheNewswire)DehydraTECH-liraglutide is showing apparent superiority to DehydraTECH-semaglutideSelect DehydraTECH-CBD formulations are showing apparent superiority to DehydraTECH-GLP-1 at 4 and 8 weeksKelowna, British Columbia – TheNewswire - August 21, 2024 – Lexaria Bioscience Corp. (Nasdaq...
read article.
(208)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Aug 19, 2024 1:30pm
Positive Results from Lexaria's Molecular Characterization S
News; $LEXX Positive Results from Lexaria's Molecular Characterization Study Monomeric form of GLP-1 drug preserved by DehydraTECH(TheNewswire) Monomeric form of GLP-1 drug preserved by
...more
(18)
•••
shawk
X
View Profile
View Bullboard History
Post by
shawk
on Aug 19, 2024 10:06am
Positive Results from Lexaria's Molecular Characterization S
Monomeric form of GLP-1 drug preserved by DehydraTECH Kelowna, British Columbia – August 19, 2024 – Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the “Company” or “Lexaria”), a
...more
(208)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Aug 16, 2024 1:02pm
Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Oral GLP-1
BREAKING NEWS: $LEXX Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Oral GLP-1 Alternatives for Diabetes and Obesity TreatmentLexaria, a global innovator in drug delivery platforms, is exploring
...more
(208)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Aug 12, 2024 2:15pm
Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Q3 2024 Fin
NEWS: $LEXX Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Q3 2024 Financial Results; Offers a Roadmap for its Key GLP-1 Study ProgramThe company provided updates for its study programs for 2024
...more
(208)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jul 31, 2024 2:02pm
Lexaria Bioscience Corp. (NASDAQ: LEXX) Produces Notable Fin
Breaking News: $LEXX Lexaria Bioscience Corp. (NASDAQ: LEXX) Produces Notable Findings in Latest Weight Loss StudyLexaria, a global innovator in drug delivery platforms, has released interim results
...more
(18)
•••
shawk
X
View Profile
View Bullboard History
Post by
shawk
on Jul 29, 2024 7:10pm
Special Report: Lexaria explains GLP-1 test results
449582_537c8f1a7a1243d0a809ebfd4627e65b.pdf (usrfiles.com)
(208)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jul 09, 2024 11:17pm
InvestorNewsBreaks - Lexaria Bioscience Corp. (NASDAQ: LEXX)
Breaking News: $LEXX InvestorNewsBreaks - Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Dosing in Second GLP-1 Human Pilot StudyLexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
New Gold and Copper Hotspot Identified – What’s Next for This Serbian Project?
Major Funding Secured! Company Closes First Round of Private Placement
Have you held units of a TD mutual fund (other than through a discount broker)? Learn more.
Geodrill Generates Revenue of $34.1M, a 13% Increase Compared to $30.3M for Q3-2023
Gold, growth and sustainability in focus for this resource company
Star Diamond Corporation Announces Third Quarter 2024 Results
This $10M Deal Could Reshape the Future of Global Creator Platforms
Coppernico Drills 19 Meters of 0.50% Copper in First 5 Holes and Applies for Additional Permits
Explained: The Psychology of Options Trading with Practical Tips
Meet the Top 5 Best Online Brokerages in Canada